A Randomized, Controlled Trial of Intermittent Preventive Treatment with Sulfadoxine‐Pyrimethamine, Amodiaquine, or the Combination in Pregnant Women in Ghana

Aug 30, 2008The Journal of infectious diseases

Preventive malaria treatments with sulfadoxine-pyrimethamine, amodiaquine, or both in pregnant women in Ghana: a controlled trial

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗

Abstract

The prevalence of anemia at delivery was similar for women receiving sulfadoxine-pyrimethamine (SP) and those receiving either amodiaquine (AQ) or a combination of AQ and SP (SPAQ).

Anemia prevalence at delivery was defined as a hemoglobin concentration of less than 11.0 g/dL.
No significant difference was observed in the rates of low birth weight between the SP, AQ, and SPAQ groups.
Women who received AQ or SPAQ reported a higher incidence of adverse events compared to those who received SP.
The overall effects of AQ and SPAQ on maternal anemia and low birth weight were comparable to those of SP.
The high frequency of adverse events associated with AQ may limit its usefulness as an alternative to SP for intermittent preventive treatment in pregnancy in Ghana.

AI simplified

BACKGROUND: The use of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment in pregnancy (IPTp) is threatened by the spread of resistance to SP. Therefore, we studied the efficacy, safety, and tolerance of amodiaquine (AQ) or the combination of AQ and SP (SPAQ) as possible alternative treatments.

METHODS: The study was performed in Ghana from June 2004 through February 2007. Women were individually randomized to receive IPTp with SP (n=1328), AQ (n= 986), or SPAQ (n=1328). Incidences of anemia, peripheral anemia, and placental parasitemia at delivery were assessed for paucigravidae, as were the birth weights of their infants. Delivery outcomes and the incidence of adverse events were investigated for all women.

RESULTS: The prevalences of anemia (as defined by a hemoglobin concentration of <11.0 g/dL) at delivery were comparable between the SP and AQ groups and between the SP and SPAQ groups. Similarly, there was no significant difference between the SP and AQ groups or between the SP and SPAQ groups with regard to the incidences of low birth weight (LBW). Women who received AQ or SPAQ were more likely to report adverse events than were those who received SP.

CONCLUSION: The effects of IPTp with AQ or SPAQ on maternal anemia and LBW were comparable to the effects of IPTp with SP; however, IPTp regimens that contain AQ are unlikely to be useful as an alternative to IPTp with SP in Ghana, because of a high frequency of associated adverse events.

TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT00146783 .

Full Text

Full text is available at the source.

View full text ↗

A Randomized, Controlled Trial of Intermittent Preventive Treatment with Sulfadoxine‐Pyrimethamine, Amodiaquine, or the Combination in Pregnant Women in Ghana

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief